Novartis AG has divulged pyrazolopyrimidine derivatives acting as methylcytosine dioxygenase TET2 inhibitors and thus reported to be useful for the treatment of cancer.
Viscient Biosciences LLC has divulged tryptanthrin derivatives acting as indoleamine 2,3-dioxygenase 2 (IDO-2) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Rome Therapeutics Inc. has divulged didehydro-3’-deoxy-4’-ethynylthymidines acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors reported to be useful for the treatment of cancer, autoimmune disease and neurological disorders.
Certain types of human papillomavirus (HPV), named high-risk types, are known to be clearly associated with 60% of invasive cervical cancer cases. Prophylactic HPV vaccines are highly effective, but there is a need for new treatment options other than surgery.
The Congress of the European Society of Medical Oncology (ESMO) held in Madrid from Oct. 20 to 24, 2023, could well add the letter W to its acronym after the four sessions on gynecological cancer that could represent a milestone in the lives of all women who suffer from cervical, ovarian, or endometrial cancer.
Among all human papillomavirus (HPV) types described so far, the two most abundant – HPV16 and HPV18 – are responsible for 71% of all cervical cancers. The vaccines currently used are effective in preventing viral infection, but have no effect on already infected or maligned cells.
China’s National Medical Products Administration (NMPA) has given the green light to Gloria Biosciences Co. Ltd.’s anti-PD-1 monoclonal antibody, zimberelimab (Yutuo, GLS-010), for treating second-line cervical cancer, making it the first immune checkpoint inhibitor approved in China for treating the disease.
Researchers at Foshan Ionova Biotherapeutics Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have disclosed fused heterocyclic compounds acting as RAS modulators reported to be useful for the treatment of cancer.
One of the main causes of cervical cancer is persistent human papillomavirus (HPV) infection, with E6 and E7 being the main oncogenic genes of HPV3. For this reason, targeting HPV proteins E6 and E7 is a promising therapeutic strategy for the treatment of this disease.
